Technological Advancements in Monoclonal Antibodies

Area of Science:

• Biopharmaceutical technology
• Intellectual property analysis
• Drug development

Background:

• Biopharmaceuticals offer innovative treatments for chronic diseases and cancers.
• Biosimilar products provide more accessible therapeutic options.
• Technological advancements are crucial for biopharmaceutical innovation.

Purpose of the Study:

• To analyze the technological and scientific advancements in biopharmaceuticals using patent and article data.
• To identify key players, trends, and innovation trajectories in the field.
• To understand the impact of biosimilar approvals on treatment accessibility.

Main Methods:

• Patent analysis using Derwent Innovation Index (DWPI) and PatentInspiration databases.
• Scientific literature search using Web of Science for the last 5 years.
• Keyword and IPC code-based search strategy across titles, summaries, and claims.

Main Results:

• Extensive patent data retrieved: 2295 individual patents and 467 families (DWPI); 769 patents and 205 families (PatentInspiration).
• Significant scientific output: 2602 articles from Web of Science.
• Monoclonal antibodies (mAbs) show prominence in scientific research and innovation.
• Analysis includes contributing organizations, geographical distribution, development, and key inventors/authors.

Conclusions:

• The biopharmaceutical landscape, particularly in mAbs and immunotherapies, is rapidly evolving.
• Anticipated regulatory approvals will drive a continuous flow of new biopharmaceutical products.
• Increased scientific and technological publications support wider availability of these essential therapies.